EE04047B1 - Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid - Google Patents

Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid

Info

Publication number
EE04047B1
EE04047B1 EE9700240A EE9700240A EE04047B1 EE 04047 B1 EE04047 B1 EE 04047B1 EE 9700240 A EE9700240 A EE 9700240A EE 9700240 A EE9700240 A EE 9700240A EE 04047 B1 EE04047 B1 EE 04047B1
Authority
EE
Estonia
Prior art keywords
ftc
zidovudine
synergistic combinations
synergistic
combinations
Prior art date
Application number
EE9700240A
Other languages
English (en)
Estonian (et)
Other versions
EE9700240A (et
Inventor
Walter Barry David
Heider St. Clair Martha
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04047(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of EE9700240A publication Critical patent/EE9700240A/xx
Publication of EE04047B1 publication Critical patent/EE04047B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
EE9700240A 1995-03-30 1996-03-28 Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid EE04047B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
EE9700240A EE9700240A (et) 1998-04-15
EE04047B1 true EE04047B1 (et) 2003-06-16

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700240A EE04047B1 (et) 1995-03-30 1996-03-28 Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid

Country Status (35)

Country Link
US (1) US6417191B1 (Direct)
EP (1) EP0817637B1 (Direct)
JP (1) JP2954357B2 (Direct)
KR (1) KR100542536B1 (Direct)
CN (1) CN1103593C (Direct)
AP (1) AP652A (Direct)
AT (1) ATE220551T1 (Direct)
AU (1) AU715213B2 (Direct)
BR (3) BRPI9607851B8 (Direct)
CA (1) CA2216634C (Direct)
CZ (1) CZ295940B6 (Direct)
DE (3) DE69622386T2 (Direct)
DK (1) DK0817637T3 (Direct)
EA (1) EA000626B3 (Direct)
EE (1) EE04047B1 (Direct)
ES (1) ES2179193T3 (Direct)
FR (1) FR05C0022I2 (Direct)
GE (1) GEP20022647B (Direct)
HU (1) HU224010B1 (Direct)
IL (1) IL117727A (Direct)
LU (1) LU91171I2 (Direct)
MX (1) MX9707316A (Direct)
MY (1) MY115461A (Direct)
NL (1) NL300195I2 (Direct)
NO (2) NO313787B1 (Direct)
NZ (1) NZ306419A (Direct)
OA (1) OA10616A (Direct)
PL (1) PL187085B1 (Direct)
PT (1) PT817637E (Direct)
RO (1) RO117995B1 (Direct)
SI (1) SI0817637T1 (Direct)
SK (1) SK283825B6 (Direct)
TR (1) TR199701074T1 (Direct)
UA (1) UA60293C2 (Direct)
WO (1) WO1996030025A1 (Direct)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
PE74799A1 (es) * 1997-05-17 1999-08-13 Glaxo Group Ltd Combinaciones antivirales
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
CA2512475C (en) 2003-01-14 2009-06-02 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ATE490470T1 (de) 2003-10-24 2010-12-15 Immunaid Pty Ltd Therapieverfahren
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
KR101964923B1 (ko) 2010-01-27 2019-04-02 비이브 헬쓰케어 컴퍼니 항바이러스 치료
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
JP6749890B2 (ja) 2014-08-12 2020-09-02 モナッシュ ユニバーシティ リンパ指向プロドラッグ
EP3347340A4 (en) 2015-09-08 2019-01-23 Monash University LYMPHENLEITUNGSPRODRUGS
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP4306524A3 (en) * 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ES2083668T5 (es) 1991-05-16 2001-06-16 Glaxo Group Ltd Combinaciones antiviricas que contienen analogos de nucleosido.
AU4079593A (en) 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
CA2262765A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
CN1103593C (zh) 2003-03-26
NO974510D0 (no) 1997-09-29
EP0817637A1 (en) 1998-01-14
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
ES2179193T3 (es) 2003-01-16
PL322532A1 (en) 1998-02-02
DK0817637T3 (da) 2002-11-11
KR19980703420A (ko) 1998-11-05
DE122005000029I2 (de) 2006-04-27
IL117727A0 (en) 1996-07-23
BRPI9607851B8 (pt) 2019-11-05
NO2005014I1 (no) 2005-06-06
AU715213B2 (en) 2000-01-20
ATE220551T1 (de) 2002-08-15
JP2954357B2 (ja) 1999-09-27
KR100542536B1 (ko) 2006-03-23
CN1185110A (zh) 1998-06-17
EP0817637B1 (en) 2002-07-17
EA199700203A1 (ru) 1998-02-26
BR9607851B1 (pt) 2009-01-13
CZ309097A3 (cs) 1998-05-13
HU224010B1 (hu) 2005-04-28
HUP9801571A3 (en) 2001-04-28
NL300195I2 (nl) 2005-11-01
AP652A (en) 1998-06-19
JPH10511682A (ja) 1998-11-10
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
CA2216634A1 (en) 1996-10-03
CA2216634C (en) 2004-07-20
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
OA10616A (en) 2001-03-15
FR05C0022I1 (Direct) 2005-06-10
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
RO117995B1 (ro) 2002-12-30
CZ295940B6 (cs) 2005-12-14
BRPI9612992B1 (pt) 2020-08-04
HK1009401A1 (en) 1999-09-10
EA000626B3 (ru) 2016-04-29
UA60293C2 (uk) 2003-10-15
US6417191B1 (en) 2002-07-09
MX9707316A (es) 1997-11-29
EE9700240A (et) 1998-04-15
DE122005000029I1 (de) 2005-10-06
NO2005014I2 (no) 2008-02-11
LU91171I9 (Direct) 2018-12-28
MY115461A (en) 2003-06-30
LU91171I2 (fr) 2005-07-04
AU5497296A (en) 1996-10-16
SK129597A3 (en) 1998-07-08
DE69622386T2 (de) 2003-02-13
FR05C0022I2 (Direct) 2005-10-21
SI0817637T1 (en) 2002-10-31
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
NO313787B1 (no) 2002-12-02
IL117727A (en) 1999-11-30
NO974510L (no) 1997-09-29
PL187085B1 (pl) 2004-05-31
EA000626B1 (ru) 1999-12-29
BR9607851A (pt) 1998-07-21

Similar Documents

Publication Publication Date Title
EE04047B1 (et) Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
BR9601693A (pt) Composição e seus usos
BR9508677A (pt) Copolímero prodesso de preparação do mesmo e composição orgânica
EE03427B1 (et) Pihusti sõlm ja selle kasutamine
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
EE04500B1 (et) Trombiini inhibiitorid, nende saamine ja kasutamine
DK0770059T3 (da) Substituerede benzamidiner, deres fremstilling og deres anvendelse som lægemidler
FI952158L (fi) Hiihtokäsine ja hihtosauva sekä niiden yhdistelmä
NO986034D0 (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse
DK0840548T3 (da) Synergistisk, herbicid sammensætning samt fremgangsmåde til fremstilling deraf
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
FI972988L (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
DK60893D0 (da) Piperidinderivater, deres fremstilling og anvendelse
EE9800451A (et) Uued imidasotriasolopürimidiinid, nende valmistamismeetod ja kasutamine ravimainetena
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
BR9610382A (pt) Composição de tratamento do cableo
FI972965A0 (fi) Uusia peptidejä, niiden valmistus ja käyttö
FI971872L (fi) Proteiinikoostumus ja sen valmistus ja käyttö sekä sitä sisältävät valmisteet ja näiden valmistus
NO972821D0 (no) 1-C-perfluoralkylglycosider, deres fremstilling og anvendelse
PT101949A (pt) Boneco com elevacao simultania de bracos, pernas e abertura de olhos
FI942331A7 (fi) Biosidisia koostumuksia ja niiden käyttö
FI970497A0 (fi) Arrangemang foer raeddningsvaeg i en byggnad med flera vaoningar
ITRM950305A0 (it) Composizione cosmetica ad azione dermoprotettiva e dermonutritiva.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

FG1Y Spc granted

Free format text: PRODUCT NAME: KIVEXA; NAT. REGISTRATION NO/DATE: C(2004)5373 20041217; FIRST REGISTRATION: EU/1/04/298/001-002

Spc suppl protection certif: C20050002 00007

Filing date: 20050512

Extension date: 20191217

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

SPCM Correction and amendment to the data concerning application for a supplementary protection certificate

Spc suppl protection certif: C20050002 00007

Extension date: 20191222

SPCX Term of validity of supplementary protection expired

Spc suppl protection certif: 00007

Extension date: 20211209